Checkpoint Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Textual) - USD ($) $ in Millions	1 Months Ended		12 Months Ended
	Jan. 01, 2019	Jan. 02, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 17, 2015
Equity Method Investment, Annual Equity Fee, Percentage		2.50%				2.50%
Fortress Biotech, Inc [Member]
Equity Method Investment, Annual Equity Fee, Percentage	2.50%		2.50%
Stock Issued During Period, Shares, New Issues	960,428	591,836
Research and Development Expense [Member]
Stock Issued During Period, Value, Issued for Services			$ 1.7	$ 2.3	$ 3.9